AbbVie Stock Performance and Risks Linked to SKYRIZI Sales
AbbVie (ABBV) is currently trading close to its 52-week high, having gained approximately 24% over the past year, significantly outperforming the S&P 500. This growth is primarily attributed to its drug SKYRIZI, which has been experiencing year-over-year growth exceeding 20%. However, as the company’s older medications decline in sales, the sustainability of this growth is under scrutiny.
In the quarter ending June 2026, AbbVie reported nearly $17 billion in revenue, with SKYRIZI accounting for about $5.5 billion of that total. This figure represents roughly one-third of the company's overall revenue. The growth of SKYRIZI, alongside AbbVie’s other major drug RINVOQ and its neuroscience products, has been a key driver for the company. In contrast, sales of HUMIRA have plummeted by 36% due to increased competition from biosimilars, and other segments like oncology and aesthetics have also seen declines.
For Your Trading Desk
Sponsor Spike Success.
The primary concern for AbbVie’s stock is the potential slowdown in SKYRIZI's growth. Several factors could contribute to this risk. Firstly, a new oral psoriasis treatment launched in March could impact SKYRIZI's market share. However, management reports that this new competitor has not yet affected SKYRIZI's sales, as it primarily attracts patients from other oral treatments, and SKYRIZI has continued to see growth in new patient starts.
Secondly, annual negotiations with payers pose a risk to pricing. AbbVie’s management describes the immunology sector as a volume business, where payers typically negotiate low-single-digit price concessions and rebates. So far, these negotiations have proceeded similarly to previous years, but any changes could affect profitability.
Concerns Over SKYRIZI's Patent Landscape and Market Position
Another significant concern is the patent landscape surrounding SKYRIZI. The drug's composition patent is set to expire in 2033, with regulatory data protection lasting until 2031. However, AbbVie has indicated that additional patents, both granted and pending, could extend protection into the mid-2030s and beyond. The company is also proactively acquiring new assets, such as Apogee Therapeutics, to bolster its immunology portfolio for future growth.
The implications of a slowdown in SKYRIZI's growth would not be immediate but would manifest as a gradual decline in growth rates, particularly as older drugs continue to lose market share. The stock has already experienced fluctuations, with a maximum drop of about 17% from its peak within the past year. The options market reflects this uncertainty, with implied volatility currently in the 73rd percentile of its one-year range, indicating a larger expected price movement than usual.
Regulatory Decisions Will Shape AbbVie's Future Stock Performance
As AbbVie approaches critical regulatory decisions, including an FDA ruling on a new subcutaneous induction dose of SKYRIZI for Crohn’s disease expected in the fall of 2026, analysts will be watching closely to see if the drug maintains its growth trajectory above 20%. The upcoming quarterly report for September 2026 will provide further insights into SKYRIZI's performance and its impact on AbbVie’s overall revenue.
Investors should remain vigilant regarding the potential risks associated with AbbVie’s stock, especially as the company navigates a competitive landscape and prepares for significant regulatory milestones. The performance of SKYRIZI will be crucial in determining the future trajectory of AbbVie’s stock price.




